FDA approves first cell-based gene therapy for rare skin disorder

StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy

“Third time’s the charm,” the old saying goes, but for Abeona Therapeutics (NASDAQ: ABEO), the second time around proved successful for the company’s first-ever pipeline candidate to make it through clinical trials. The FDA approved Abeona’s Zevaskyn (prademagene zamikeracel) as the first (and so far only) cell-based gene therapy to be authorized for recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue skin disorder caused…

FDA approves first cell-based gene therapy for rare skin disorder